Generated by AI
MaxCyte, Inc. is a life sciences tools company focused on cell engineering for cell and gene therapy development. MaxCyte designs and commercializes non-viral flow electroporation systems, proprietary processing assemblies, and consumables that help biotechnology and pharmaceutical companies introduce biological cargo into cells with precision and consistency. Its platform is used across drug discovery, translational research, and biomanufacturing, supporting applications in gene editing, immuno-oncology, and other advanced cell-based medicines. The company also offers licensing arrangements tied to partner programs, making its technology part of broader therapeutic development workflows. Headquartered in Rockville, Maryland, MaxCyte serves a global customer base involved in next-generation cell therapeutics and related research.
Website9713 Key West Avenue
Rockville, MD, 20850
United States
The latest articles about MXCT.
Summary of Oct 28's posts. Generated by AI.
No summary yet.
Summary of Aug 19's posts. Generated by AI.
MaxCyte (MXCT) stock dips as the company agrees to buy Akron BioProducts for $151.8M in cash and stock. Read more here.
No summary yet.
Summary of Oct 28's posts. Generated by AI.
Investors talking about MXCT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.